Spyre Therapeutics reports positive Phase 1 data for SPY003 with ~85-day half-life; Q3 net loss $11.2M

Spyre Therapeutics, Inc.

SPY003 Phase 1 interim results show half-life of ~85 days, supporting potential quarterly or twice annual maintenance dosing.
SPY003 well tolerated, no serious adverse events; safety profile consistent with anti-IL-23 class.
Q3 2025 net loss of $11.2M, compared to $69.0M in Q3 2024; R&D expenses $45.2M.
Pro forma cash $782.7M as of Sep 30, 2025, including $296.5M net from October 2025 public offering.
Company expects 6 proof-of-concept readouts in 2026 from SKYLINE and SKYWAY Phase 2 trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.